血小板因子4(PF4)檢測試劑盒(化學發(fā)光免疫分析法)
CLIA Kit for Platelet Factor 4 (PF4)
CXCL4; SCYB4; Chemokine C-X-C-Motif Ligand 4; Oncostatin-A; Iroplact
- 編號SCA172Mu
- 物種Mus musculus (Mouse，小鼠)相同的名稱，不同的物種。
- 實驗方法雙抗夾心
- 反應時長2h, 40min
- 檢測范圍2.74-2,000pg/mL
- 靈敏度最小可檢測劑量小于等于0.99pg/mL.
- 樣本類型Serum, platelet-poor plasma and cell culture supernates
- 下載英文說明書 中文說明書
- 規(guī)格48T96T96T*596T*1096T*100
- 價格¥ 3629¥ 5184¥ 23328¥ 44064¥ 362880
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
實驗結果圖
標準曲線圖
通過ISO 9001、ISO 13485質量體系認證
特異性
本試劑盒用于檢測血小板因子4(PF4)，經(jīng)檢測與其它相似物質無明顯交叉反應。
由于受到技術及樣本來源的限制，不可能完成對所有相關或相似物質交叉反應檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質有交叉反應。
回收率
分別于定值血清及血漿樣本中加入一定量的血小板因子4(PF4)（加標樣品），重復測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 90-99 | 95 |
| EDTA plasma(n=5) | 98-105 | 102 |
| heparin plasma(n=5) | 85-102 | 97 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定，每個樣本使用同一試劑盒重復測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的血小板因子4(PF4)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中血小板因子4(PF4)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 83-102% | 95-103% | 83-97% | 80-103% |
| EDTA plasma(n=5) | 85-97% | 87-103% | 86-101% | 84-103% |
| heparin plasma(n=5) | 80-96% | 90-99% | 80-101% | 90-103% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本的準備；
2. 加樣（標準品及樣本）100µL，37°C孵育1小時；
3. 吸棄，加檢測溶液A100μL，37°C孵育1小時；
4. 洗板3次；
5. 加檢測溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加底物100µL，37°C孵育10分鐘；
8. 讀數(shù)。
實驗原理
將血小板因子4(PF4)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標準品或標本，其中的血小板因子4(PF4)與連接于固相載體上的抗體結合，然后加入生物素化的血小板因子4(PF4)抗體，將未結合的生物素化抗體洗凈后，加入HRP標記的親和素，再次徹底洗滌后加入底物。加入底物后會產(chǎn)生輝光型光信號。發(fā)射光強度和樣品中的血小板因子4(PF4)呈正相關。用化學發(fā)光儀測定相對光單位（RLU），計算樣品濃度。
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| APA172Mu01 | 血小板因子4(PF4)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA172Mu01 | 血小板因子4(PF4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA172Mu02 | 血小板因子4(PF4)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA172Mu01 | 血小板因子4(PF4)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA172Mu02 | 血小板因子4(PF4)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA172Mu71 | 血小板因子4(PF4)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| LAA172Mu81 | 血小板因子4(PF4)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| SEA172Mu | 血小板因子4(PF4)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA172Mu | 血小板因子4(PF4)檢測試劑盒(化學發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA172Mu | 血小板因子4(PF4)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSA172Mu01 | 血小板因子4(PF4)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics | Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic rats[PubMed: 20601223] |
| Basic Research in Cardiology | Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation[PubMed: 22899170] |
| PLoS One | Platelets Recognize Brain-Specific Glycolipid Structures, Respond to Neurovascular Damage and Promote Neuroinflammation[PubMed: PMC3608633] |
| Diving and Hyperbaric Medicine | Effect of splenectomy on platelet activation and decompression sickness outcome in a rat model of decompression[Pubmed:25311322] |
| Journal of Functional Foods | A?Phellinus baumii–based supplement containing?Salvia miltiorrhiza?Bunge improves atherothrombotic profiles through endothelial nitric oxide synthase and cyclooxygenase pathwaysin vitro?and?in vivo[science:S1756464616300676] |
| Plos one | Aspirin, but Not Tirofiban Displays Protective Effects in Endotoxin Induced Lung Injury[pubmed:27583400] |
| international journal of molecular sciences | Evidence of the Role of R-Spondin 1 and Its Receptor Lgr4 in the Transmission of Mechanical Stimuli to Biological Signals for Bone Formation.[pubmed:28272338] |
| Experimental?and?Therapeutic?Medicine | Feasibility of improving platelet?rich plasma therapy by using chitosan with high platelet activation ability[pubmed:28450960] |
| Reproductive Toxicology | Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in rats[Pubmed: 30528429] |
| INTERNATIONAL JOURNAL OF CARDIOLOGY | Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation[Pubmed: 30857843] |
| Available at SSRN 3335365? | Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers[] |
| journal of biotechnology | Newly Identified HNP‐F from Human Neutrophil Peptide 1 Promotes Hemostasis[Pubmed: 30927490] |
| Data in Brief | Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation[] |
| journal of thoracic and cardiovascular surgery | Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular Markers[Pubmed: 32812629] |
| Marine Drugs | The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents[Pubmed: 31533230] |
| Thrombosis Research | Feasibility study of use of rabbit blood to evaluate platelet activation by medical devices[Pubmed: 31838449] |
| Nat Commun | The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets[34099640] |
| Vaccine | The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats[Pubmed:35183388] |